secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001493152-23-008242
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma reports FY2022 net loss $14.3M; cash $55.2M; IND timeline for LP-184/LP-284 in 2023
--------------------------------------------------------------------------------

- FY2022 net loss $14.3M ($1.31/sh) vs $12.4M ($1.13/sh) in FY2021; cash and equivalents $55.2M (Dec 31, 2022) down from $70.7M.
- IND submission for LP-184 expected April 2023; LP-284 IND and first-in-human Phase 1 trials targeted for mid-2023.
- Phase 2 Harmonic trial (LP-300) activated 5 sites across 12 US locations; first patient dosing anticipated Q2 2023.
- Formed wholly-owned subsidiary Starlight Therapeutics for CNS cancers; STAR-001 clinical trials planned for late 2023/early 2024.
- RADR platform surpassed 25 billion oncology datapoints; target of 50 billion in coming year; cash runway into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/0001493152-23-008242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223008242/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer